A systematic review of prion therapeutics in experimental models

Brain

Volumn 129, Issue 9, 2006, Pages 2241-2265

  Trevitt, Clare R ^a   Collinge, John ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Creutzfeldt Jakob disease; Experimental models; Prion; Therapeutics; Transmissible spongiform encephalopathy

Indexed keywords

4' IODOESORUBICIN; ACRIDINE DERIVATIVE; AMPHOTERICIN B; ANTIMONIOTUNGSTATE; CPG OLIGODEOXYNUCLEOTIDE; CURCUMIN; CYSTEINE PROTEINASE INHIBITOR; DEXTRAN SULFATE; DIMETHYL SULFOXIDE; DOXYCYCLINE; HEPARAN SULFATE; IMATINIB; IMMUNOMODULATING AGENT; METHOTREXATE; MS 8209; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PENTOSAN POLYSULFATE; PHENOTHIAZINE DERIVATIVE; PHTHALOCYANINE DERIVATIVE; POLYAMINE; POLYAMINE DERIVATIVE; POLYCLONAL ANTIBODY; POLYENE ANTIBIOTIC AGENT; PORPHYRIN DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; STATINE DERIVATIVE; STEROID; SURAMIN; TETRACYCLINE; TETRAPYRROLE DERIVATIVE; UNINDEXED DRUG; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; CONGO RED; GLYCOSAMINOGLYCAN; PRION PROTEIN; TETRACYCLINE DERIVATIVE;

BOVINE SPONGIFORM ENCEPHALOPATHY; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; FATALITY; HUMAN; IN VITRO STUDY; NEUROPROTECTION; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; REVIEW; SCRAPIE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED KINGDOM; ANIMAL; CATTLE; DISEASE MODEL; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; ANTIMALARIALS; ANTIVIRAL AGENTS; CATTLE; CONGO RED; CREUTZFELDT-JAKOB SYNDROME; DISEASE MODELS, ANIMAL; ENCEPHALOPATHY, BOVINE SPONGIFORM; GLYCOSAMINOGLYCANS; HUMANS; IMMUNOTHERAPY; POLYAMINES; PRION DISEASES; PRPC PROTEINS; TETRACYCLINES;

EID: 33749236787     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl150     Document Type: Review

References (241)

1. Adjou KT, Demaimay R, Lasmezas C, Deslys JP, Seman M, Dormont D. MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie. Antimicrob Agents Chemother 1995; 39: 2810-2.
2. Adjou KT, Demaimay R, Lasmézas CI, Seman M, Deslys JP, Dormont D. Differential effects of a new amphotericin B derivative, MS-8209, on mouse BSE, scrapie: implications for the mechanism of action of polyene antibiotics. Res Virol 1996; 147: 213-8.
3. Adjou KT, Demaimay R, Deslys JP, Lasmézas CI, Beringue V, Demart S, et al. MS-8209, a water-soluble amphotericin B derivative, affects both scrapie agent replication and PrPres accumulation in Syrian hamster scrapie. J Gen Virol 1999; 80: 1079-85.
4. Adjou KT, Privat N, Demart S, Deslys JP, Seman M, Hauw JJ, et al. MS-8209, an amphotericin B analogue, delays the appearance of spongiosis, astrogliosis and PrPres accumulation in the brain of scrapie-infected hamsters. J Comp Pathol 2000; 122: 3-8.
5. Adjou KT, Simoneau S, Sales N, Lamoury F, Dormont D, Papy-GarciaD, et al. A novel generation of heparan sulfate mimetics for the treatment of prion diseases. J Gen Virol 2003; 84: 2595-603.
6. Aguzzi A, Heppner FL, Heikenwalder M, Prinz M, Mertz K, Seeger H, et al. Immune system and peripheral nerves in propagation of prions to CNS. Br Med Bull 2003; 66: 141-59.
7. Alderson P, Green S, Higgins JPT, editors. Cochrane reviewers handbook 4.2.3. Chichester UK: John Wiley & Sons, Ltd; 2005.
8. Allen LB, Cochran KW. Acceleration of scrapie in mice by target-organ treatment with interferon inducers. Ann N Y Acad Sci 1977; 284: 676-81.
9. Amyx H, Salazar AM, Gajdusek CD, Gibbs CJ. Chemotherapeutic trials in experimental slow virus diseases. Neurology 1984; 34 (Suppl. 1).
10. Bach S, Talarek N, Andrieu T, Vierfond JM, Mettey Y, Galons H, et al. Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat Biotechnol 2003; 21: 1075-81.
11. Barret A, Tagliavini F, Forloni G, Bate C, Salmona M, Colombo L, et al. Evaluation of quinacrine treatment for prion diseases. J Virol 2003; 77: 8462-9.
12. Bate C, Rutherford S, Gravenor M, Reid S, Williams A. Cyclo-oxygenase inhibitors protect against prion-induced neurotoxicity in vitro. Neuroreport 2002; 13: 1933-8.
13. Bate C, Reid S, Williams A. Phospholipase A2 inhibitors or platelet-activating factor antagonists prevent prion replication. J Biol Chem 2004a; 279: 36405-11.
14. Bate C, Salmona M, Diomede L, Williams A. Squalestatin cures prion-infected neurones and protects against prion neurotoxicity. J Biol Chem 2004b; 279: 14983-90.
15. Baxter A, Fitzgerald BJ, Hutson JL, McCarthy AD, Motteram JM, Ross BC, et al. Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J Biol Chem 1992; 267: 11705-8.
16. Bendheim PE, Barry RA, DeArmond SJ, Stites DP, Prusiner SB. Antibodies to a scrapie prion protein. Nature 1984; 310: 418-21.
17. Beringue V, Lasmézas CI, Adjou KT, Demaimay R, Lamoury F, Deslys JP, et al. Inhibiting scrapie neuroinvasion by polyene antibiotic treatment of SCID mice. J Gen Virol 1999; 80: 1873-7.
18. Beringue V, Adjou KT, Lamoury F, Maignien T, Deslys JP, Race R, et al. Opposite effects of dextran sulfate 500, the polyene antibiotic MS-8209, and Congo red on accumulation of the protease-resistant isoform of PrP in the spleens of mice inoculated intraperitoneally with the scrapie agent. J Virol 2000a; 74: 5432-40.
19. rse accumulation in the spleen of scrapie-infected mice. Arch Virol Suppl 2000b; 16: 39-56.
20. Beringue V, Mallinson G, Kaisar M, Tayebi M, Sattar Z, Jackson G, et al. Regional heterogeneity of cellular prion protein isoforms in the mouse brain. Brain 2003; 126: 2065-73.
21. Beringue V, Vilette D, Mallinson G, Archer F, Kaisar M, Tayebi M, et al. PrPSc binding antibodies are potent inhibitors of prion replication in cell lines. J Biol Chem 2004; 279: 39671-6.
22. Bertsch U, Winklhofer KF, Hirschberger T, Bieschke J, Weber P, Hartl FU, et al. Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets. J Virol 2005; 79: 7785-91.
23. Bessen RA, Marsh RF. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J Virol 1994; 68: 7859-68.
24. Birkett CR, Hennion RM, Bembridge DA, Clarke MC, Chree A, Bruce ME, et al. Scrapie strains maintain biological phenotypes on propagation in a cell line in culture. EMBO J 2001; 20: 3351-8.
25. Bolton DC, McKinley MP, Prusiner SB. Identification of a protein that purifies with the scrapie prion. Science 1982; 218: 1309-11.
26. Borchelt DR, Scott M, Taraboulos A, Stahl N, Prusiner SB. Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells. J Cell Biol 1990; 110: 743-52.
27. Bossers A, Schreuder BEC, Muileman IH, Belt PB, Smits MA. PrP genotype contributes to determining survival times of sheep with natural scrapie. J Gen Virol 1996; 77: 2669-73.
28. Brown KL, Stewart K, Ritchie DL, Mabbott NA, Williams A, Fraser H, et al. Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells. Nat Med 1999; 5: 1308-12.
29. Bruce ME, Fraser H, McBride PA, Scott JR, Dickinson AG. The basis of strain variation in scrapie. In: Prusiner SB, Collinge J, Powell J, Anderton B, editors. Prion diseases in human and animals. London: Ellis Horwood; 1992.
30. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997; 389: 498-501.
31. Büeler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, et al. Mice devoid of PrP are resistant to scrapie. Cell 1993; 73: 1339-47.
32. Sc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol Med 1994; 1: 19-30.
33. Cardinale A, Filesi I, Vetrugno V, Pocchiari M, Sy MS, Biocca S. Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc formation. J Biol Chem 2005; 280: 685-94.
34. Caspi S, Halimi M, Yanai A, Sasson SB, Taraboulos A, Gabizon R. The antiprion activity of Congo red. Putative mechanism. J Biol Chem 1998; 273: 3484-9.
35. Caughey B, Race RE. Potent inhibition of scrapie-associated PrP accumulation by Congo red. J Neurochem 1992; 59: 768-71.
36. Caughey B, Raymond GJ. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J Biol Chem 1991; 266: 18217-23.
37. Caughey B, Raymond GJ. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol 1993; 67: 643-50.
38. Caughey B, Ernst D, Race RE. Congo red inhibition of scrapie agent replication. J Virol 1993; 67: 6270-2.
39. Caughey B, Brown K, Raymond GJ, Katzenstein GE, Thresher W. Binding of the protease-sensitive form of prion protein PrP to sulfated glycosaminoglycan and Congo red. J Virol 1994; 68: 2135-41.
40. Caughey WS, Raymond LD, Horiuchi M, Caughey B. Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci USA 1998; 95: 12117-22.
41. Caughey B, Raymond LD, Raymond GJ, Maxson L, Silveira J, Baron GS. Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J Virol 2003; 77: 5499-502.
42. Chabry J, Caughey B, Chesebro B. Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J Biol Chem 1998; 273: 13203-7.
43. Chabry J, Priola SA, Wehrly K, Nishio J, Hope J, Chesebro B. Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J Virol 1999; 73: 6245-50.
44. Cochran KW. Failure of adenine arabinoside to modify scrapie in mice. J Gen Virol 1971; 13: 353-4.
45. Collinge J. Variant Creutzfeldt-Jakob disease. Lancet 1999; 354: 317-23.
46. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 2001; 24: 519-50.
47. Collinge J, Palmer MS, Sidle KCL, Gowland I, Medori R, Ironside J, et al. Transmission of fatal familial insomnia to laboratory animals. Lancet 1995; 346: 569-70.
48. Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996; 383: 685-90.
49. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, Masters CL. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 2002; 52: 503-6.
50. Cordeiro Y, Machado F, Juliano L, Juliano MA, Brentani RR, Foguel D, et al. DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation. J Biol Chem 2001; 276: 49400-9.
51. Crozet C, Flamant F, Bencsik A, Aubert D, Samarut J, Baron T. Efficient transmission of two different sheep scrapie isolates in transgenic mice expressing the ovine PrP gene. J Virol 2001; 75: 5328-34.
52. Crozet C, Lin YL, Mettling C, Mourton-Gilles C, Corbeau P, Lehmann S, et al. Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations. J Cell Sci 2004; 117: 5591-7.
53. Culmsee C, Zhu X, Yu QS, Chan SL, Camandola S, Guo Z, et al. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem 2001; 77: 220-8.
54. Daude N, Marella M, Chabry J. Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J Cell Sci 2003; 116: 2775-9.
55. de Gioia L, Selvaggini C, Ghibaudi E, Diomede L, Bugiani O, Forloni G, et al. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. J Biol Chem 1994; 269: 7859-62.
56. Deleault NR, Geoghegan JC, Nishina K, Kascsak R, Williamson RA, Supattapone S. PrPres amplification reconstituted with purified prion proteins and synthetic polyanions. J Biol Chem 2005; 280: 26873-9.
57. Demaimay R, Adjou K, Lasmézas C, Lazarini F, Cherifi K, Seman M, et al. Pharmacological studies of a new derivative of amphotericin B, MS-8209, in mouse and hamster scrapie. J Gen Virol 1994; 75: 2499-503.
58. Demaimay R, Adjou KT, Beringue V, Demart S, Lasmézas CI, Deslys JP, et al. Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals. J Virol 1997; 71: 9685-9.
59. Demaimay R, Harper J, Gordon H, Weaver D, Chesebro B, Caughey B. Structural aspects of Congo red as an inhibitor of protease-resistant prion protein formation. J Neurochem 1998; 71: 2534-41.
60. Demaimay R, Race R, Chesebro B. Effectiveness of polyene antibiotics in treatment of transmissible spongiform encephalopathy in transgenic mice expressing syrian hamster PrP only in neurons. J Virol 1999; 73: 3511-3.
61. Demaimay R, Chesebro B, Caughey B. Inhibition of formation of protease-resistant prion protein by Trypan Blue, Sirius Red, other Congo Red analogs. Arch Virol Suppl 2000; 16: 277-83.
62. Demart S, Fournier JG, Creminon C, Frobert Y, Lamoury F, Marce D, et al. New insight into abnormal prion protein using monoclonal antibodies. Biochem Biophys Res Commun 1999; 265: 652-7.
63. Desgranges P, Barbaud C, Caruelle JP, Barritault D, Gautron J. A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle. FASEB J 1999; 13: 761-6.
64. Diaz-Nido J, Wandosell F, Avila J. Glycosaminoglycans, beta-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides 2002; 23: 1323-32.
65. Dickinson AG, Fraser H. Scrapie: effect of Dh gene on incubation period of extraneurally injected agent. Heredity 1972; 29: 91-3.
66. Diringer H, Ehlers B. Chemoprophylaxis of scrapie in mice. J Gen Virol 1991; 72: 457-60.
67. Doh-ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000; 74: 4894-7.
68. Doh-ura K, Ishikawa K, Murakami-Kubo I, Sasaki K, Mohri S, Race R, et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 2004; 78: 4999-5006.
69. Donofrio G, Heppner FL, Polymenidou M, Musahl C, Aguzzi A. Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J Virol 2005; 79: 8330-8.
70. Egger M, Davey-Smith G, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. London: BMJ; 2001.
71. Ehlers B, Diringer H. Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 1984; 65: 1325-30.
72. Ehlers B, Rudolph R, Diringer H. The reticuloendothelial system in scrapie pathogenesis. J Gen Virol 1984; 65: 423-8.
73. Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci USA 2001; 98: 9295-9.
74. Engelstein R, Grigoriadis N, Greig NH, Ovadia H, Gabizon R. Inhibition of P53-related apoptosis had no effect on PrP(Sc) accumulation and prion disease incubation time. Neurobiol Dis 2005; 18: 282-5.
75. Ertmer A, Gilch S, Yun SW, Flechsig E, Klebl B, Stein-Gerlach M, et al. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. J Biol Chem 2004; 279: 41918-27.
76. Farquhar CF, Dickinson AG. Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J Gen Virol 1986; 67: 463-73.
77. Farquhar C, Dickinson A, Bruce M. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet 1999; 353: 117.
78. Feraudet C, Morel N, Simon S, Volland H, Frobert YF, Creminon C, et al. Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J Biol Chem 2004; 280: 11247-58.
79. Field EJ, Joyce G, Keith A. Failure of interferon to modify scrapie in the mouse. J Gen Virol 1969; 5: 149-50.
80. Forloni G, Iussich S, Awan T, Colombo L, Angeretti N, Girola L, et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci USA 2002; 99: 10849-54.
81. Fraser H, Dickinson AG. Pathogenesis of scrapie in the mouse: the role of the spleen. Nature 1970; 226: 462-3.
82. Fraser H, Dickinson AG. Studies of the lymphoreticular system in the pathogenesis of scrapie: the role of spleen and thymus. J Comp Pathol 1978; 88: 563-73.
83. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, et al. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 2001; 22: 993-1005.
84. Gabizon R, McKinley MP, Groth D, Prusiner SB. Immunoaffinity purification and neutralization of scrapie prion infectivity. Proc Natl Acad Sci USA 1988; 85: 6617-21.
85. Gabizon R, Meiner Z, Halimi M, Ben-Sasson SA. Heparin-like molecules bind differentially to prion-proteins and change their intracellular metabolic fate. J Cell Physiol 1993; 157: 319-25.
86. Gauczynski S, Peyrin JM, Haïk S, Leucht C, Hundt C, Rieger R, et al. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J 2001; 20: 5863-75.
87. Gianni L, Bellotti V, Gianni AM, Merlini G. New drug therapy of amyloidoses: resorption of AL-type deposits with 4′-iodo-4′- deoxydoxorubicin. Blood 1995; 86: 855-61.
88. Sc and delays onset of prion disease. EMBO J 2001; 20: 3957-66.
89. Gilch S, Wopfner F, Renner-Muller I, Kremmer E, Bauer C, Wolf E, et al. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J Biol Chem 2003; 278: 18524-31.
90. Goni F, Knudsen E, Schreiber F, Scholtzova H, Pankiewicz J, Carp R, et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 2005; 133: 413-21.
91. Gresser I, Pattison IH. An attempt to modify scrapie in mice by the administration of interferon. J Gen Virol 1968; 3: 295-7.
92. Gresser I, Maury C, Chandler RL. Failure to modify scrapie in mice by administration of interferon or anti-interferon globulin. J Gen Virol 1983; 64: 1387-9.
93. Griffith JS. Self replication and scrapie. Nature 1967; 215: 1043-4.
94. Guenther K, Deacon RM, Perry VH, Rawlins JN. Early behavioural changes in scrapie-affected mice and the influence of dapsone. Eur J Neurosci 2001; 14: 401-9.
95. Haig DA, Clark MC. The effect of β-propiolactone on the scrapie agent. J Gen Virol 1968; 3: 281-3.
96. Harris DA. Trafficking, turnover and membrane topology of PrP. Br Med Bull 2003; 66: 71-85.
97. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004; 10: 187-92.
98. Heppner FL, Musahl C, Arrighi I, Klein MA, Rülicke T, Oesch B, et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 2001; 294: 178-82.
99. Hijazi N, Shaked Y, Rosenmann H, Ben Hur T, Gabizon R. Copper binding to PrP(C) may inhibit prion disease propagation. Brain Res 2003; 993: 192-200.
100. Hill AF, Desbruslais M, Joiner S, Sidle KCL, Gowland I, Collinge J. The same prion strain causes vCJD and BSE. Nature 1997; 389: 448-50.
101. Hill AF, Joiner S, Linehan J, Desbruslais M, Lantos PL, Collinge J. Species barrier independent prion replication in apparently resistant species. Proc Natl Acad Sci USA 2000; 97: 10248-53.
102. Horiuchi M, Caughey B. Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J 1999; 18: 3193-203.
103. Hsiao KK, Scott M, Foster D, Groth DF, DeArmond SJ, Prusiner SB. Spontaneous neurodegeneration in transgenic mice with mutant prion protein. Science 1990; 250: 1587-90.
104. Hundt C, Peyrin JM, Haïk S, Gauczynski S, Leucht C, Rieger R, et al. Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. EMBO J 2001; 20: 5876-86.
105. Ingrosso L, Ladogana A, Pocchiari M. Congo red prolongs the incubation period in scrapie-infected hamsters. J Virol 1995; 69: 506-8.
106. Jackson GS, Hosszu LLP, Power A, Hill AF, Kenney J, Saibil H, et al. Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science 1999; 283: 1935-7.
107. Jackson GS, Murray I, Hosszu LLP, Gibbs N, Waltho JP, Clarke AR, et al. Location and properties of metal-binding sites on the human prion protein. Proc Natl Acad Sci USA 2001; 98: 8531-5.
108. Kaneko K, Vey M, Scott M, Pilkuhn S, Cohen FE, Prusiner SB. COOH-terminal sequence of the cellular prion protein directs subcellular trafficking and controls conversion into the scrapie isoform. Proc Natl Acad Sci USA 1997a; 94: 2333-8.
109. Kaneko K, Zulianello L, Scott M, Cooper CM, Wallace AC, James TL, et al. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci USA 1997b; 94: 10069-74.
110. Kascsak RJ, Rubenstein R, Merz PA, Tonna DeMasi M, Fersko R, Carp RI, et al. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol 1987; 61: 3688-93.
111. Khalili-Shirazi A, Quaratino S, Londei M, Summers L, Tayebi M, Clarke AR, et al. Protein conformation significantly influences immune responses to prion protein. J Immunol 2005; 174: 3256-63.
112. Kim CL, Karino A, Ishiguro N, Shinagawa M, Sato M, Horiuchi M. Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. J Gen Virol 2004a; 85: 3473-82.
113. Kim CL, Umetani A, Matsui T, Ishiguro N, Shinagawa M, Horiuchi M. Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies. Virology 2004b; 320: 40-51.
114. Kimberlin RH, Walker CA. Antiviral compound effective against experimental scrapie. Lancet 1979; 2: 591-2.
115. Kimberlin RH, Walker CA. The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection. Arch Virol 1983; 78: 9-18.
116. Kimberlin RH, Walker CA. Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate and some other polyanions. Antimicrob Agents Chemother 1986; 30: 409-13.
117. Kirby L, Birkett CR, Rudyk H, Gilbert IH, Hope J. In vitro cell-free conversion of bacterial recombinant PrP to PrP(res) as a model for conversion. J Gen Virol 2003; 84: 1013-20.
118. Kishida H, Sakasegawa Y, Watanabe K, Yamakawa Y, Nishijima M, Kuroiwa Y, et al. Non-glycosylphosphatidylinositol (GPI)-anchored recombinant prion protein with dominant-negative mutation inhibits PrPSc replication in vitro. Amyloid 2004; 11: 14-20.
119. Klein MA, Frigg R, Flechsig E, Raeber AJ, Kalinke U, Bluethmann H, et al. A crucial role for B cells in neuroinvasive scrapie. Nature 1997; 390: 687-90.
120. Klein M, Frigg R, Raeber A, Flechsig E, Hegyi I, Zinkernagel RM, et al. PrP expression in B-lymphocytes is not required for prion neuroinvasion. Nat Med 1998a; 4: 1429-33.
121. Klein TR, Kirsch D, Kaufmann R, Riesner D. Prion rods contain small amounts of two host sphingolipids and revealed by thin-layer chromatography and mass spectrometry. Biol Chem 1998b; 379: 666.
122. Klein MA, Kaeser PS, Schwarz P, Weyd H, Xenarios I, Zinkernagel RM, et al. Complement facilitates early prion pathogenesis. Nat Med 2001; 7: 488-92.
123. Klunk WE, Debnath ML, Koros AM, Pettegrew JW. Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. Life Sci 1998; 63: 1807-14.
124. Klunk WE, Debnath ML, Pettegrew JW. Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging 1994; 15: 691-8.
125. Kocisko DA, Caughey B. Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo. J Virol 2006; 80: 1044-6.
126. Kocisko DA, Baron GS, Rubenstein R, Chen J, Kuizon S, Caughey B. New inhibitors of scrapie-associated prion protein formation in a library of 2,000 drugs and natural products. J Virol 2003; 77: 10288-94.
127. Kocisko DA, Morrey JD, Race RE, Chen J, Caughey B. Evaluation of new cell culture inhibitors of protease-resistant prion protein against scrapie infection in mice. J Gen Virol 2004; 85: 2479-83.
128. Kocisko DA, Engel AL, Harbuck K, Arnold KM, Olsen EA, Raymond LD, et al. Comparison of protease-resistant prion protein inhibitors in cell cultures infected with two strains of mouse and sheep scrapie. Neurosci Lett 2005; 388: 106-11.
129. Kocisko DA, Caughey WS, Race RE, Roper G, Caughey B, Morrey JD. A porphyrin increases survival time of mice after intracerebral prion infection. Antimicrob Agents Chemother 2006a; 50: 759-61.
130. Kocisko DA, Vaillant A, Lee KS, Arnold KM, Bertholet N, Race RE, et al. Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob Agents Chemother 2006b; 50: 1034-44.
131. Sc)-specific epitope defined by a monoclonal antibody. Nature 1997; 390: 74-7.
132. Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001; 98: 9836-41.
133. Krasemann S, Groschup MH, Harmeyer S, Hunsmann G, Bodemer W. Generation of monoclonal antibodies against human prion proteins in PrP0/0 mice. Mol Med 1996; 2: 725-34.
134. Ladogana A, Casaccia P, Ingrosso L, Cibati M, Salvatore M, Xi Y, et al. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J Gen Virol 1992; 73: 661-5.
135. Lasmezas CI, Deslys J-P, Robain O, Jaegly A, Beringue V, Peyrin J-M, et al. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 1997; 275: 402-5.
136. Leucht C, Simoneau S, Rey C, Vana K, Rieger R, Lasmezas CI, et al. The 37 kDa/67 kDa laminin receptor is required for PrPSc propagation in scrapie-infected neuronal cells. EMBO Rep 2003; 4: 290-5.
137. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001; 21: 8370-7.
138. Lipford GB, Heeg K, Wagner H. Bacterial DNA as immune cell activator. Trends Microbiol 1998; 6: 496-500.
139. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-21.
140. Lucassen R, Nishina K, Supattapone S. In vitro amplification of protease-resistant prion protein requires free sulfhydryl groups. Biochemistry 2003; 42: 4127-35.
141. Mabbott NA, Bruce ME, Botto M, Walport MJ, Pepys MB. Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat Med 2001; 7: 485-7.
142. Mabbott NA, McGovern G, Jeffrey M, Bruce ME. Temporary blockade of the tumor necrosis factor receptor signaling pathway impedes the spread of scrapie to the brain. J Virol 2002; 76: 5131-9.
143. Mabbott NA, Mackay F, Minns F, Bruce ME. Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie. Nat Med 2000a; 6: 719-20.
144. Mabbott NA, Williams A, Farquhar CF, Pasparakis M, Kollias G, Bruce ME. Tumor necrosis factor alpha-deficient, but not interleukin-6-deficient, mice resist peripheral infection with scrapie. J Virol 2000b; 74: 3338-44.
145. Mabbott NA, Young J, McConnell I, Bruce ME. Follicular dendritic cell dedifferentiation by treatment with an inhibitor of the lymphotoxin pathway dramatically reduces scrapie susceptibility. J Virol 2003; 77: 6845-54.
146. Magri G, Clerici M, Dall'Ara P, Biasin M, Caramelli M, Casalone C, et al. Decrease in pathology and progression of scrapie after immunisation with synthetic prion protein peptides in hamsters. Vaccine 2005; 23: 2862-8.
147. Mallucci G, Collinge J. Rational targeting for prion therapeutics. Nat Rev Neurosci 2005; 6: 23-34.
148. Mallucci GR, Ratté S, Asante EA, Linehan J, Gowland I, Jefferys JGR, et al. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J 2002; 21: 202-10.
149. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003; 302: 871-4.
150. Mangé A, Milhavet O, McMahon HEM, Casanova D, Lehmann S. Effect of amphotericin B on wild-type and mutated prion proteins in cultured cells: putative mechanism of action in transmissible spongiform encephalopathies. J Neurochem 2000a; 74: 754-62.
151. Mangé A, Nishida N, Milhavet O, McMahon HEM, Casanova D, Lehmann S. Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures. J Virol 2000b; 74: 3135-40.
152. Manuelidis L, Fritch W, Zaitsev I. Dapsone to delay symptoms in Creutzfeldt-Jakob disease. Lancet 1998; 352: 456.
153. Marella M, Lehmann S, Grassi J, Chabry J. Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release. J Biol Chem 2002; 227: 25457-64.
154. May BC, Fafarman AT, Hong SB, Rogers M, Deady LW, Prusiner SB, et al. Potent inhibition of scrapie prion replication in cultured cells by bisacridines. Proc Natl Acad Sci USA 2003; 100: 3416-21.
155. McBride PA, Wilson MI, Eikelenboom P, Tunstall A, Bruce ME. Heparan sulfate proteoglycan is associated with amyloid plaques and neuroanatomically targeted PrP pathology throughout the incubation period of scrapie-infected mice. Exp Neurol 1998; 149: 447-54.
156. McFarlin DE, Raff MC, Simpson E, Nehlsen SH. Scrapie in immunologically deficient mice. Nature 1971; 233: 336.
157. McKenzie D, Kaczkowski J, Marsh R, Aiken J. Amphotericin B delays both scrapie agent replication and PrP-res accumulation early in infection. J Virol 1994; 68: 7534-6.
158. Medori R, Montagna P, Tritschler HJ, LeBlanc A, Cortelli P, Tinuper P, et al. Fatal familial insomnia: a second kindred with mutation of prion protein gene at codon 178. Neurology 1992; 42: 669-70.
159. Meier P, Genoud N, Prinz M, Maissen M, Rulicke T, Zurbriggen A, et al. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. Cell 2003; 113: 49-60.
160. Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, et al. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995; 92: 2959-63.
161. Milhavet O, Mangé A, Casanova D, Lehmann S. Effect of Congo red on wild-type and mutated prion proteins in cultured cells. J Neurochem 2000; 74: 222-30.
162. Millhauser GL. Copper binding in the prion protein. Acc Chem Res 2004; 37: 79-85.
163. Miyamoto K, Nakamura N, Aosasa M, Nishida N, Yokoyama T, Horiuchi H, et al. Inhibition of prion propagation in scrapie-infected mouse neuroblastoma cell lines using mouse monoclonal antibodies against prion protein. Biochem Biophys Res Commun 2005; 335: 197-204.
164. Mohan J, Bruce ME, Mabbott NA. Follicular dendritic cell dedifferentiation reduces scrapie susceptibility following inoculation via the skin. Immunology 2005; 114: 225-34.
165. Montrasio F, Frigg R, Glatzel M, Klein MA, Mackay F, Aguzzi A, et al. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science 2000; 288: 1257-9.
166. Sc)-induced toxicity in rat cortical cell cultures. Eur J Pharmacol 1993; 246: 261-7.
167. Murakami-Kubo I, Doh-ura K, Ishikawa K, Kawatake S, Sasaki K, Kira J, et al. Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J Virol 2004; 78: 1281-8.
168. Nakamura N, Miyamoto K, Shimokawa M, Nishida N, Mohri S, Kitamoto T, et al. Generation of antibodies against prion protein by scrapie-infected cell immunization of PrP(0/0) mice. Hybrid Hybridomics 2003; 22: 263-6.
169. Nordstrom EK, Luhr KM, Ibanez C, Kristensson K. Inhibitors of the mitogen-activated protein kinase kinase 1/2 signaling pathway clear prion-infected cells from PrPSc. J Neurosci 2005; 25: 8451-6.
170. Nunziante M, Kehler C, Maas E, Kassack MU, Groschup M, Schatzl HM. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication. J Cell Sci 2005; 118: 4959-73.
171. Oishi T, Hagiwara K, Kinumi T, Yamakawa Y, Nishijima M, Nakamura K, et al. Effects of beta-sheet breaker peptide polymers on scrapie-infected mouse neuroblastoma cells and their affinities to prion protein fragment PrP(81-145). Org Biomol Chem 2003; 1: 2626-9.
172. Orem NR, Geoghegan JC, Deleault NR, Kascsak R, Supattapone S. Copper (II) ions potently inhibit purified PrPres amplification. J Neurochem 2006; 96: 1409-15.
173. Outram GW, Dickinson AG, Fraser H. Developmental maturation of susceptibility to scrapie in mice. Nature 1973; 241: 536-7.
174. Outram GW, Dickinson AG, Fraser H. Reduced susceptibility to scrapie in mice after steroid administration. Nature 1974; 249: 855-6.
175. Outram GW, Dickinson AG, Fraser H. Slow encephalopathies, inflammatory responses and arachis oil. Lancet 1975; 1: 198-200.
176. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 527-9.
177. Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G, et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001; 412: 739-43.
178. Perrier V, Wallace AC, Kaneko K, Safar J, Prusiner SB, Cohen FE. Mimicking dominant negative inhibition of prion replication through structure-based drug design. Proc Natl Acad Sci USA 2000; 97: 6073-8.
179. Perrier V, Kaneko K, Safar J, Vergara J, Tremblay P, DeArmond SJ, et al. Dominant-negative inhibition of prion replication in transgenic mice. Proc Natl Acad Sci USA 2002; 99: 13079-84.
180. Perrier V, Solassol J, Crozet C, Frobert Y, Mourton-Gilles C, Grassi J, et al. Anti-PrP antibodies block PrP replication in prion-infected cell cultures by accelerating PrP degradation. J Neurochem 2004; 89: 454-63.
181. Pocchiari M, Schmittinger S, Masullo C. Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. J Gen Virol 1987; 68: 219-23.
182. Pocchiari M, Casaccia P, Ladogana A. Amphotericin B: a novel class of antiscrapie drugs. J Infect Dis 1989; 160: 795-802.
183. Poli G, Ponti W, Carcassola G, Ceciliani F, Colombo L, Dall'Ara P, et al. In vitro evaluation of the anti-prionic activity of newly synthesized congo red derivatives. Arzneimittelforschung 2003; 53: 875-88.
184. Poli G, Martino PA, Villa S, Carcassola G, Giannino ML, Dall'Ara P, et al. Evaluation of anti-prion activity of congo red and its derivatives in experimentally infected hamsters. Arzneimittelforschung 2004; 54: 406-15.
185. Pollera C, Lucchini B, Formentin E, Bareggi S, Poli G, Ponti W. Evaluation of anti-prionic activity of clioquinol in an in vivo model (Mesocricetus auratus). Vet Res Commun 2005; 29 (Suppl 2): 253-5.
186. Porter DD, Porter HG, Cox NA. Failure to demonstrate a humoral immune response to scrapie infection in mice. J Immunol 1973; 111: 1407-10.
187. Priola SA, Caughey B. Inhibition of scrapie-associated PrP accumulation: probing the role of glycosaminoglycans in amyloidogenesis. Mol Neurobiol 1994; 8: 113-20.
188. Priola SA, Raines A, Caughey WS. Porphyrin and phthalocyanine antiscrapie compounds. Science 2000; 287: 1503-6.
189. Priola SA, Raines A, Caughey W. Prophylactic and therapeutic effects of phthalocyanine tetrasulfonate in scrapie-infected mice. J Infect Dis 2003; 188: 699-705.
190. Proske D, Gilch S, Wopfner F, Schatzl HM, Winnacker EL, Famulok M. Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem 2002; 3: 717-25.
191. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216: 136-44.
192. Prusiner SB. Shattuck lecture - neurodegenerative diseases and prions. N Engl J Med 2001; 344: 1516-26.
193. Prusiner SB, Groth D, Serban A, Koehler R, Foster D, Torchia M, et al. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci USA 1993; 90: 10608-12.
194. Ravid M, Keizman IK, Sohar E. Effect of a single dose of dimethyl sulphoxide on renal amyloidosis. Lancet 1977; 1: 730-1.
195. Ravid M, Shapira J, Lang R, Kedar I. Prolonged dimethylsulphoxide treatment in 13 patients with systemic amyloidosis. Ann Rheum Dis 1982; 41: 587-92.
196. Raymond GJ, Olsen EA, Lee KS, Raymond LD, Bryant PK III, Baron GS, et al. Inhibition of protease-resistant prion protein formation in a transformed deer cell line infected with chronic wasting disease. J Virol 2006; 80: 596-604.
197. Reddy TR, Mutter R, Heal W, Guo K, Gillet VJ, Pratt S, et al. Library design, synthesis, and screening: pyridine dicarbonitriles as potential prion disease therapeutics. J Med Chem 2006; 49: 607-15.
198. Rhie A, Kirby L, Sayer N, Wellesley R, Disterer P, Sylvester I, et al. Characterization of 2′-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. J Biol Chem 2003; 278: 39697-705.
199. Roikhel VM, Fokina GI, Pogodina VV. Influence of aminasine on experimental scrapie in mice. Acta Virol 1984; 28: 321-4.
200. Rudyk H, Vasiljevic S, Hennion RM, Birkett CR, Hope J, Gilbert IH. Screening Congo Red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells. J Gen Virol 2000; 81: 1155-64.
201. Ryou C, Legname G, Peretz D, Craig JC, Baldwin MA, Prusiner SB. Differential inhibition of prion propagation by enantiomers of quinacrine. Lab Invest 2003; 83: 837-43.
202. Sailer A, Bueler H, Fischer M, Aguzzi A, Weissmann C. No propagation of prions in mice devoid of PrP. Cell 1994; 77: 967-8.
203. Schonberger O, Horonchik L, Gabizon R, Papy-Garcia D, Barritault D, Taraboulos A. Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis. Biochem Biophys Res Commun 2003; 312: 473-9.
204. Schwarz A, Kratke O, Burwinkel M, Riemer C, Schultz J, Henklein P, et al. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett 2003; 350: 187-9.
205. Sellarajah S, Lekishvili T, Bowring C, Thompsett AR, Rudyk H, Birkett CR, et al. Synthesis of analogues of congo red and evaluation of their anti-prion activity. J Med Chem 2004; 47: 5515-34.
206. Sethi S, Lipford G, Wagner H, Kretzschmar H. Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet 2002; 360: 229-30.
207. Shaked GM, Fridlander G, Meiner Z, Taraboulos A, Gabizon R. Protease-resistant and detergent-insoluble prion protein is not necessarily associated with prion infectivity. J Biol Chem 1999; 274: 17981-6.
208. Shaked GM, Engelstein R, Avraham I, Kahana E, Gabizon R. Dimethyl sulfoxide delays PrP(sc) accumulation and disease symptoms in prion-infected hamsters. Brain Res 2003; 983: 137-43.
209. Shibuya S, Higuchi J, Shin RW, Tateishi J, Kitamoto T. Protective prion protein polymorphisms against sporadic Creutzfeldt-Jakob disease [letter]. Lancet 1998; 351: 419.
210. C in cultured cells. J Biol Chem 1995; 270: 30221-9.
211. Sigurdsson EM, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp R, et al. Immunization delays the onset of prion disease in mice. Am J Pathol 2002; 161: 13-7.
212. Sigurdsson EM, Brown DR, Alim MA, Scholtzova H, Carp R, Meeker HC, et al. Copper chelation delays the onset of prion disease. J Biol Chem 2003a; 278: 46199-202.
213. Sigurdsson EM, Sy MS, Li R, Scholtzova H, Kascsak RJ, Kascsak R, et al. Antiprion antibodies for prophylaxis following prion exposure in mice. Neurosci Lett 2003b; 336: 185-7.
214. Snow AD, Kisilevsky R, Willmer J, Prusiner SB, DeArmond SJ. Sulfated glycosaminoglycans in amyloid plaques of prion diseases. Acta Neuropathol 1989; 77: 337-42.
215. Solassol J, Crozet C, Perrier V, Leclaire J, Beranger F, Caminade AM, et al. Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. J Gen Virol 2004; 85: 1791-9.
216. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 1998; 4: 822-6.
217. Soto C, Kascsack RJ, Saborío GP, Aucouturier P, Wisniewski T, Prelli F, et al. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 2000; 355: 192-7.
218. Souan L, Tal Y, Felling Y, Cohen IR, Taraboulos A, Mor F. Modulation of proteinase-K resistant prion protein by prion peptide immunization. Eur J Immunol 2001; 31: 2338-46.
219. Supattapone S, Nguyen HOB, Cohen FE, Prusiner SB, Scott MR. Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci USA 1999; 96: 14529-34.
220. Supattapone S, Wille H, Uyechi L, Safar J, Tremblay P, Szoka FC, et al. Branched polyamines cure prion-infected neuroblastoma cells. J Virol 2001; 75: 3453-61.
221. Tagliavini F, McArthur RA, Canciani B, Giaccone G, Porro M, Bugiani M, et al. Effectiveness of anthracycline against experimental prion disease in syrian hamsters. Science 1997; 276: 1119-22.
222. Tagliavini F, Forloni G, Colombo L, Rossi G, Girola L, Canciani B, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol 2000; 300: 1309-22.
223. Tal Y, Souan L, Cohen IR, Meiner Z, Taraboulos A, Mor F. Complete Freund's adjuvant immunization prolongs survival in experimental prion disease in mice. J Neurosci Res 2003; 71: 286-90.
224. Taraboulos A, Scott M, Semenov A, Avraham D, Laszlo L, Prusiner SB. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J Cell Biol 1995; 129: 121-32.
225. Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 2001; 49: 561-74.
226. Tateishi J. Antibiotics and antivirals do not modify experimentally- induced Creutzfeldt-Jakob disease in mice. J Neurol Neurosurg Psychiatry 1981; 44: 723-4.
227. Tatzelt J, Prusiner SB, Welch WJ. Chemical chaperones interfere with the formation of scrapie prion protein. EMBO J 1996; 15: 6363-73.
228. Telling GC, Scott M, Mastrianni J, Gabizon R, Torchia M, Cohen FE, et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 1995; 83: 79-90.
229. Telling GC, Parchi P, DeArmond SJ, Cortelli P, Montagna P, Gabizon R, et al. Evidence for the conformation of the pathologic isoformof the prion protein enciphering and propagating prion diversity. Science 1996; 274: 2079-82.
230. Tilly G, Chapuis J, Vilette D, Laude H, Vilotte JL. Efficient and specific down-regulation of prion protein expression by RNAi. Biochem Biophys Res Commun 2003; 305: 548-51.
231. Vetrugno V, Cardinale A, Filesi I, Mattei S, Sy MS, Pocchiari M, et al. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. Biochem Biophys Res Commun 2005; 338: 1791-7.
232. White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003; 422: 80-3.
233. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-5.
234. Williamson RA, Peretz D, Smorodinsky N, Bastidas R, Serban H, Mehlhorn I, et al. Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. Proc Natl Acad Sci USA 1996; 93: 7279-82.
235. Sc in scrapie-infected mouse neuroblastoma cells. Biol Chem 2000; 381: 463-9.
236. Sc-dependent cell-free formation of protease-resistant prion protein. EMBO J 2001; 20: 377-86.
237. Woody AY, Reisbig RR, Woody RW. Spectroscopic studies of Congo Red binding to RNA polymerase. Biochim Biophys Acta 1981; 655: 82-8.
238. Worthington M. Interferon system in mice infected with the scrapie agent. Infect Immun 1972; 6: 643-5.
239. Worthington M, Clark R. Lack of effect of immunosuppression on scrapie infection in mice. J Gen Virol 1971; 13: 349-51.
240. Xi YG, Ingrosso L, Ladogana A, Masullo C, Pocchiari M. Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation. Nature 1992; 356: 598-601.
241. Yudovin-Farber I, Azzam T, Metzer E, Taraboulos A, Domb AJ. Cationic polysaccharides as antiprion agents. J Med Chem 2005; 48: 1414-20.